Design of ^<99m>Tc-labled compound for diagnosis of metastatic tumor in bone

用于诊断骨转移性肿瘤的^<99m>Tc标记化合物的设计

• 批准号: 21791172
• 负责人: 上原 知也
• 金额: $ 2.75万
• 依托单位: Chiba University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Young Scientists (B)
• 财政年份: 2009
• 资助国家: 日本
• 起止时间: 2009 至 2010
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-21791172/
• 关键词: 放射性医薬品; D-penicillamine; オリゴアスパラギン酸; SPECT

Increased permeability of blood vessels in diseased bone suggested that ^<99m>Tc-labeled compound of higher molecular size and hydroxyapatite binding would be useful to detect the diseased bone. Since ^<99m>Tc-labeled oligo-aspartic acid showed higher molecular size and higher hydroxyapatite binding than those of ^<99m>Tc-methylenediphosphonate (^<99m>Tc-MDP), to evaluate the molecular design of ^<999m>Tc-labeled oligo-aspartic acid, the accumulation of ^<99m>Tc-labeled oligo-aspartic acid in bone metastatic tumor of rat was compared with ^<99m>Tc-MDP. The tumor to normal region ratios of ^<99m>Tc-labeled oligo-aspartic acids were higher than those of ^<99m>Tc-MDP. These results suggested that the present molecular design would be useful to image bone metastatic tumor.

病变骨中血管通透性的增加表明，<99m>具有更高分子尺寸和羟基磷灰石结合的13 Tc标记的化合物将有助于检测病变骨。由于<99m>~（13）Tc标记的寡聚天冬氨酸比~（13）Tc-亚甲基二膦酸盐（~（13）Tc-MDP）具有更大的分子尺寸和更高的羟基磷灰石结合率<99m><99m>，为了评价~（13）Tc标记的寡聚天冬氨酸的分子设计<999m>，比较了~（13）<99m>Tc-标记的寡聚天冬氨酸和~（13）Tc-MDP在大鼠骨转移瘤中的蓄积<99m>。标记寡聚天冬氨酸的肿瘤与正常区域的比值<99m>高于标记<99m>MDP的肿瘤与正常区域的比值。这些结果表明，本分子设计将是有用的骨转移瘤的形象。

项目成果

骨疾患部に選択的に集積する^<99m>Tc標識薬剤の開発

开发^<99m>Tc标记药物，选择性地积聚在骨病区域

• 发表时间: 2010
• 作者: 吉田好雄;黒川哲司;澤村陽子;品川明子; 小辻文和; 辻川哲也; 岡沢秀彦;澤村陽子;澤村陽子;上原知也
• 通讯作者: 上原知也